Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating the Evidence for CYP2C19 Inhibitor Classifications: A Scoping Review.

Clinical pharmacology and therapeutics - 1 Nov 2025

Malavé Jean G, Lopez Andrés, Doan Thi, Cicali Emily J, Desta Zeruesenay, McDonough Caitrin W, Cavallari Larisa H

Abstract excerpt

The Food and Drug Administration (FDA) Table of Inhibitors and the Flockhart Table™ are important references for identifying CYP2C19 inhibitors. Accurate inhibitor classification is essential for evaluating phenoconversion and managing drug-drug interactions. The objective of this study was to assess the concordance between inhibitor classifications according to the FDA and Flockhart tables and pharmacokinetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CYP2C19 gene
Share to Phenotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to United States

Share to Cytochrome P-450 CYP2C19

Share to Drug Interactions

Share to United States Food and Drug Administration

Source

Identifiers

PMID: 40391533
DOI: 10.1002/cpt.3712

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating the Evidence for CYP2C19 Inhibitor Classifications: A Scoping Review.PMID 40391533Read ↗

Impact of cytochrome P450 2C19 polymorphisms on the clinical efficacy and safety of voriconazole: an update systematic review and meta-analysis.Semantic proximity Read ↗

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.Semantic proximity Read ↗

CYP450 Genotype—Phenotype Concordance Using the Geneva Micrococktail in a Clinical SettingSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole TherapySemantic proximity Read ↗

Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels -- a study based on therapeutic drug monitoring dataSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.Semantic proximity Read ↗

Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.Semantic proximity Read ↗

Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels: A study based on therapeutic drug monitoring data.Semantic proximity Read ↗

Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.Semantic proximity Read ↗

Self-reported pharmacogenetic medication use in the <i>Our Future Health</i> cohortSemantic proximity Read ↗

How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.